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Equine herpesvirus type 1 (EHV-1) is an alphaherpesvirus related to pseudorabies virus
(PRV) and varicella-zoster virus (VZV). This virus is one of the major pathogens affecting
horses worldwide. EHV-1 is responsible for respiratory disorders, abortion, neonatal foal
death and equine herpes myeloencephalopathy (EHM). Over the last decade, EHV-1
has received growing attention due to the frequent outbreaks of abortions and/or EHM
causing serious economical losses to the horse industry worldwide. To date, there are no
effective antiviral drugs and current vaccines do not provide full protection against EHV-
1-associated diseases. Therefore, there is an urgent need to gain a better understanding
of the pathogenesis of EHV-1 in order to develop effective therapies. The main objective
of this review is to provide state-of-the-art information on the pathogenesis of EHV-1.
We also highlight recent findings on EHV-1 immune evasive strategies at the level of the
upper respiratory tract, blood circulation and endothelium of target organs allowing the
virus to disseminate undetected in the host. Finally, we discuss novel approaches for
drug development based on our current knowledge of the pathogenesis of EHV-1.
Keywords: pathogenesis, immune evasion, prevention, therapies, Equine Herpesvirus type 1
EQUINE HERPESVIRUS TYPE 1 (EHV-1)
In 1933, Dimock and Edwards documented epidemic virus abortion in mares in Kentucky (Dimock
and Edwards, 1933). The virus was first designated as “equine abortion virus” and later renamed
equine herpesvirus type 1. EHV-1 was first isolated in 1966 from cases of abortion and paralysis
(Saxegaard, 1966). The virus was recognized by the Herpesvirus Study group of the International
Committee for Taxonomy of Viruses in 1988 (Roizman et al., 1992). EHV-1 is among nine equid
herpesviruses that have been identified so far (Davison et al., 2009). EHV-1 shares its classification
with other animal herpesviruses of agricultural importance including bovine herpesvirus type 1
(BHV-1) and pseudorabies virus (PRV). The EHV-1 virion is 200–250 nm in diameter and consists
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of four main structural components characteristic of
herpesviruses: genome, capsid, tegument, and envelop. The
viral genome consists of a linear double stranded DNA of
150 kbp. EHV-1 virion structure, replication cycle and cell-
associated spread are not covered in this review, as several
excellent reviews on alphaherpesviruses already addressed these
topics in more detail (Whitley and Roizman, 2001; Mettenleiter
et al., 2009).
THE PATHOGENESIS OF EHV-1
Here, we provide an overview of the key steps in the pathogenesis
of EHV-1 in the horse that will be relevant to thoroughly
understand its immune evasive mechanisms.
Introduction
EHV-1 is a highly contagious pathogen and is usually transmitted
via direct contact with infectious secretions (saliva, nasal
discharge) or via inhalation of infectious aerosols (Patel
et al., 1982). Fetal or placental tissues that contain high
virus loads may also serve as a possible source of infection
(Reed and Toribio, 2004).
EHV-1 Primary Replication in the Upper
Respiratory Tract (URT)
Upon entry into the host, EHV-1 first replicates in a restricted
plaquewise manner in the epithelial cells lining the URT,
including nasal septum, nasopharynx, and trachea (van Maanen,
2002; Gryspeerdt et al., 2010; Figure 1.1a). In vivo, EHV-
1-induced plaques were observed in the epithelium of the
nasal mucosa starting from 2 to 7 days post-inoculation (dpi)
(Gryspeerdt et al., 2010). In ex vivo experiments, single infected
epithelial cells were visible at 12 h post-inoculation (hpi) and
EHV-1-induced plaques were observed in the epithelium of
equine nasal and nasopharyngeal explants starting from 24 hpi
(Vandekerckhove et al., 2010; Negussie et al., 2016). Primary
EHV-1 infection of several tissues of the URT results in the
destruction and erosion of the epithelium and in nasal shedding
starting from 1 to 14 dpi (Gibson et al., 1992; Gryspeerdt
et al., 2010; Figure 1.1b). Ultimately, the destruction of the
respiratory epithelial cells and local inflammation causes mild
clinical symptoms (e.g., serous nasal discharge and fever) in
the horse after 2–10 dpi (Allen and Bryans, 1986). Most EHV-
1 infections are self-limiting in adult horses and accompanying
respiratory symptoms disappear from 9 to 12 dpi (Gibson et al.,
1992). However, young horses can develop more severe clinical
symptoms consisting of high fever, swelling of the submandibular
and retropharyngeal lymph nodes (Coggins, 1979; Patel et al.,
1982). The nasal discharge can become mucopurulent, due to
secondary bacterial infections, and contribute to the development
of rhinopneumonitis (Thomson et al., 1979; McGavin and
Zachary, 2007).
Recently, Van Cleemput and colleagues demonstrated that
certain environmental circumstances stimulate the replication
of EHV-1 in the URT. They showed that plant pollen contain
proteases that selectively and irreversibly alter intercellular
junctions (ICJ) of columnar equine respiratory epithelial cells
(Van Cleemput et al., 2019a). The authors demonstrated that
EHV-1 infection of ex vivo respiratory mucosal explants is greatly
enhanced following pollen protease pretreatment, suggesting
that pollen-induced loss of respiratory epithelial barrier function
facilitates EHV-1 invasion. Interestingly, pollen concentrations in
the outdoor air have been shown to peak between late winter and
spring, a period that coincides with high incidence of seasonally
observed EHV-1-associated symptoms (e.g., respiratory disease,
abortion and EHM) (Goehring et al., 2006; D’Amato et al.,
2007). Similarly, it was demonstrated that pretreatment of ex vivo
respiratory mucosal explants and EREC with deoxynivalenol
(DON), a mycotoxin mainly present in equine feeds, alters
respiratory epithelial integrity and predisposes these cells to
EHV-1 infection (Van Cleemput et al., 2019b). It was proposed
that the inhalation of mycotoxins from contaminated hay, grains
and roughage disrupts the respiratory epithelial integrity and
subsequently promotes EHV-1 infection. Most importantly, the
authors dissected the mechanisms of EHV-1 invasion through
the respiratory epithelium. Equine mucosal explants were first
treated with EGTA or N-acetylcysteine (NAC), two chelating
agents, to disrupt respiratory epithelial ICJ and were subsequently
inoculated with EHV-1. The number of EHV-1 plaques, the
plaque latitude and infectious virus titer were significantly
increased in explants pretreated with EGTA or NAC compared
to untreated ones (Van Cleemput et al., 2017). Interestingly, the
authors demonstrated that disruption of ICJ results in enhanced
EHV-1 binding to explant basolateral surfaces. Consequently, it
was hypothesized that EHV-1 binding/entry receptor is expressed
basolaterally on respiratory epithelial cells and is only exposed
when the integrity of the epithelium is compromised. So far, the
EHV-1 basolateral receptor remains uncharacterized.
EHV-1 Replication in Draining Lymph
Nodes and Cell-Associated Viremia
Following infection of the respiratory epithelium, EHV-1 crosses
the basement membrane (BM) by the use of single infected
leukocytes (Kydd et al., 1994; Vandekerckhove et al., 2010;
Figure 1.1c). These cells were mainly identified as CD172a+ cells
(myeloid origin) followed by T lymphocytes and B lymphocytes
(Gryspeerdt et al., 2010; Vandekerckhove et al., 2010; Baghi
et al., 2014). Upon crossing the BM, EHV-1-infected leukocytes
penetrate the connective tissues and reaches the bloodstream
and the draining lymph nodes (Figure 1.1d). Within 24–48 hpi,
EHV-1 antigens as well as infectious virus can be detected in
submandibular, retropharyngeal and bronchial lymph nodes. The
infection is amplified in the draining lymph nodes with discharge
of infected leukocytes, via the efferent lymph, into the blood
circulation (Kydd et al., 1994). As a result, EHV-1 initiates a
cell-associated viremia in peripheral blood mononuclear cells
(PBMC) to disseminate in the host (Siedek et al., 1999; van der
Meulen et al., 2000; Figure 1.2). Viremia can be detected starting
from 1 dpi and persists for 14 days (Gryspeerdt et al., 2010).
The cell-associated viremia is a prerequisite for EHV-1 spread to
target organs such as the central nervous system (CNS) and/or
pregnant uterus. The spread of EHV-1 to the local lymph nodes
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FIGURE 1 | Schematic representation of the pathogenesis of EHV-1 in the horse. (1) Primary EHV-1 replication in the epithelial cells of the upper respiratory tract: (a)
EHV-1 infection (green); (b) Viral spread within the respiratory epithelium and viral shedding; (c) EHV-1 crosses the basement membrane (BM) and penetrates the
lamina propria via the use of single infected leukocytes; (d) EHV-1 reaches the blood circulation and draining lymph nodes; (e) EHV-1 enters nerve endings of the
peripheral nervous system and spreads in the retrograde direction to the trigeminal ganglia (TG). (2) EHV-1 replication in the draining lymph nodes and establishment
of a cell-associated viremia in peripheral blood mononuclear cells (PBMC). (3) Establishment of EHV-1 latency in TG neurons and respiratory lymphoid tissues. (4)
Via a cell-associated viremia in PBMC, EHV-1 is transported to target organs such as the pregnant uterus (4a), the central nervous system (CNS) (4b) or the eye (4c),
where it initiates a secondary replication in the endothelial cells lining the blood vessels of this organ. gray, respiratory tract; red, blood circulation; yellow, lymph
nodes; blue, TG; green, spinal cord. Drawings are partially based on SMART servier medical art templates.
and in the bloodstream leads to clinical symptoms including
lymph node swelling and fever (Patel et al., 1982; Allen and
Bryans, 1986).
Establishment of a Latent EHV-1
Infection in the Peripheral Nervous
System (PNS) and in Respiratory
Associated Lymphoid Tissues
After primary replication in the horse respiratory epithelium,
EHV-1 enters nerve endings of the PNS, including those
coming from the trigeminal ganglia (TG), sympathetic
and parasympathetic neurons that innervate the epithelium
(Figure 1.1e; Van Cleemput et al., 2017). EHV-1 particles travel
via retrograde transport to the sensory and autonomic peripheral
ganglia. A hallmark of herpesviruses is the establishment
of a reactivable, latent infection in its host (Grinde, 2013).
Therefore, EHV-1 establishes a lifelong latent infection in
horse PNS neurons (Figure 1.3). An in vivo study of Slater
and colleagues presented evidence of a latent EHV-1 infection
in horses. Two months following the initial intranasal EHV-1
inoculation, the authors administered a reactivation stimulus
(e.g., dexamethasone) to asymptomatic ponies. EHV-1 infectious
virus and viral DNA were subsequently detected in the TG
of infected ponies by cocultivation and PCR assays (Slater
et al., 1994a,b). These results were confirmed by another study
demonstrating the presence of specific latency-associated
transcripts (LAT) in TG of EHV-1-infected horses by in situ
hybridization (Baxi et al., 1995). EHV-1 has also been shown
to establish latency in respiratory associated lymphoid tissues
(e.g., mandibular, retropharyngeal and bronchial lymph nodes).
Latent EHV-1 was detected by PCR and recovered by co-
cultivation from lymphoid tissues draining the respiratory
tract of experimentally inoculated ponies (Welch et al., 1992;
Kydd et al., 1994; Slater et al., 1994a). Additional studies
stating that EHV-1 establishes latency in lymphoid tissues,
failed to conclusively demonstrate the presence of LATs in
these tissues (Pusterla et al., 2010, 2012; Goehring, 2017;
Giessler et al., 2020). Finally, circulating T lymphocytes
have been defined as a predominant site of EHV-1 latency.
Using southern hybridization and PCR techniques, Chesters
and colleagues first demonstrated that PBMC express a
putative LAT antisense to and overlapping the 3′ end of
the EHV-1 immediate-early gene (ORF64) (Chesters et al.,
1997). An in vitro study showed that EHV-1 reactivates
from CD8+ T lymphocytes upon mitogen stimulation (e.g.,
phytohaemagglutin ad pokeweed mitogen) (Smith et al., 1998).
It was estimated that 1/50,000 PBMC are latently infected
with EHV-1. However, these results must be interpreted with
caution as the authors also failed to demonstrate the presence
of LAT in these cells and/or confirm the findings obtained by
Chesters and colleagues.
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Upon stress-induced reactivation months or years after
primary infection, EHV-1 replication occurs and particles spread
back from infected T lymphocytes or from infected TG neurons
through anterograde transport to the respiratory epithelium
where the infection is initiated. The presence of an EHV-
1 receptor located at the basolateral side of the respiratory
epithelium is a key advantage for the virus to efficiently bind
and infect epithelial cells upon reactivation (Van Cleemput et al.,
2017). So far, there is no direct evidence of EHV-1 neuronal
spread from the PNS (e.g., TG) to the CNS (e.g., brain). Cycles of
EHV-1 latency and reactivation in horses lead to the shedding of
infectious virus and transmission to new hosts, allowing the virus
to be maintained in herds. In addition, latently infected cells are
masked from immune surveillance and constitute a permanent
reservoir of the virus that is difficult to eliminate by conventional
antiviral therapies and vaccine strategies. It is now estimated that
the majority of horses (> 60%) are latently infected by EHV-1
(Lunn et al., 2009).
Secondary EHV-1 Replication in the
Pregnant Uterus, CNS and/or Eye
Once in the blood circulation, infected leukocytes can adhere and
subsequently transfer EHV-1 to the endothelial cells (EC) lining
the blood vessels of target organs such as the pregnant uterus or
CNS. The infection of EC located in the vasculature of the late-
gravid uterus or CNS is mediated by cell-to-cell contacts between
infected PBMC and EC (Goehring et al., 2011). The adhesion
molecules present on the surface of both EC [e.g., intracellular
adhesion molecule (ICAM), E-selectin, P-selectin] and leukocyte
[e.g., α4β1 (VLA-4), αLβ2 (LFA-1), and αvβ3 integrins] have been
shown to play an important role in the infection of the vascular
endothelium (Smith et al., 2001; Laval et al., 2015b).
Secondary replication in the EC of the pregnant uterus causes
vasculitis and multifocal thrombosis that particularly affect small
arteriolar branches in the glandular layer of the endometrium
at the base of the microcotyledons (Edington et al., 1991; Smith
et al., 1992, 1993; Figure 1.4a). This event leads to avascular
necrosis and edema of the endometrium. A widespread EC
infection can cause detachment of the fetal membranes, thus
leading to the abortion of a virus-negative fetus. Less extensive
uterine vascular pathology allows EHV-1 to invade the fetus
through the uteroplacental barrier and leads to the abortion of
a virus-infected fetus. In EHV-1-positive fetuses, infected EC are
present in blood vessels of the allantochorion and umbilical cord
(Smith et al., 1997). The aborted fetus shows multiple lesions,
including subcutaneous edema, pulmonary edema and splenic
enlargement (Corner et al., 1963; Machida et al., 1997). At late
stage of gestation, transplacental EHV-1 infection often results
in the delivery of a live infected foal that dies within a few days.
Whether or not abortion occurs may depend on the hormonal
activity during pregnancy. The production of high levels of
cortisone, progesterone and estrogens at late stage of pregnancy
may alter the immune system of the mare (Smith et al., 1996).
EHV-1-induced abortion typically occurs in the last trimester of
pregnancy. The incubation period of abortion following viremia,
arising from either a primary infection or a reactivation of latent
virus, varies between 9 days and 4 months (Allen, 1999, 2002).
EHV-1-induced abortions usually occur in single mares within a
group, suggesting that abortion resulted from viral reactivation
rather than from newly acquired respiratory infection (Doll and
Bryans, 1963). Mares may experience respiratory symptoms and
fever prior to abortion but can also abort without showing any
clinical symptoms. The reproductive potential of the mare is
usually not affected, and the virus is rapidly cleared from the
reproductive tract.
Secondary replication in the EC lining the blood vessels of
the CNS can cause vasculitis with or without local hemorrhage
and thrombo-ischemic necrosis, in the brain and spinal cord
(Figure 1.4b; Edington et al., 1986; Wilson, 1997). The lack of
nutrients and oxygen and the elevated levels of inflammatory
cytokines cause neurons to degenerate, eventually leading
to equine herpes myeloencephalopathy (EHM) (Jackson and
Kendrick, 1971; Wilson, 1997). Neurological symptoms go from
ataxia to a complete fore and hind limb paralysis. Other clinical
signs comprise fecal and/or urinary incontinence, head tilting, tail
paralysis, distal limb edema and blindness (Jackson and Kendrick,
1971; van Maanen et al., 2001; Borchers et al., 2006; Gryspeerdt
et al., 2011). The prognosis for non-recumbent horses is favorable
but full recovery can take months. However, recumbent horses
usually develop fatal complications and require euthanasia. The
incubation period of EHV-1-induced neurological disorders can
vary between 6 and 8 days (Mumford et al., 1994). Several risks
factors, including the age (elder), breed (Standardbred), gender
(female), season (late autumn, winter, spring), and type of EHV-
1 strain (neurovirulent) have been associated with an increased
risk to develop EHM (Goehring et al., 2006; Henninger et al.,
2007; Allen, 2008; Perkins et al., 2009; Pusterla et al., 2016).
The neurovirulent EHV-1 strain presents a single nucleotide
polymorphism (SNP) in the catalytic subunit of the viral DNA
polymerase (ORF30), causing a substitution of asparagine (N)
by aspartic acid (D) at amino acid position 752 (Nugent
et al., 2006). It was demonstrated that more than 86% of
neuropathogenic outbreaks are caused by strains encoding D752
and more than 95% of non-neuropathogenic outbreaks were
caused by virus strains encoding DNA pol N752. Horses infected
with neurovirulent strains also showed a higher and longer
viremia compared to those infected with non-neurovirulent
strains and were more likely to develop neurological disorders
(Allen and Breathnach, 2006). These results were confirmed
by targeted mutation of the D752 to the N752 genotype in a
neurovirulent isolate which resulted in attenuation of virulence,
reduced levels of viremia and reduced capacity to cause EHM
(Goodman et al., 2007).
Finally, secondary replication of EHV-1 in the vasculature
of the eye can cause multifocal chorioretinal lesions in infected
horses (Figure 1.4c; Matthews, 2004). This type of lesion is
typically caused by endothelial damage with subsequent ischemic
injury to the chorioretina that may result from direct infection
of the vascular endothelium following viremia. Most EHV-1-
induced ocular infections are subclinical but sometimes, diffuse
lesions may lead to extensive retinal destruction and blindness.
The frequency of EHV-1 ocular lesions varies between 50 and
90% in experimentally infected horses (Hussey et al., 2013).
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THE MECHANISMS OF EHV-1 IMMUNE
EVASION
In this section, we discuss the current knowledge on the
pathogenesis of EHV-1 with an emphasis on its immune evasive
strategies developed at the level of the URT, blood circulation and
endothelium of target organs in order to survive and disseminate
undetected in the host.
Restricted EHV-1 Replication in the URT:
A Strategy to Control Innate Immune
Defenses
Recently, Van Cleemput and colleagues showed that EHV-1
exploits antimicrobial equine β-defensins (eBD) to initiate viral
replication and spread within the URT. Pretreatment of primary
respiratory epithelial cells (EREC) with eBD increased EHV-1
virion binding and infection of these cells. It was demonstrated
that EHV-1 virions are resistant to the antimicrobial properties
of eBD through the action of EHV-1 gM, which stabilizes the
viral envelope and protects it from eBD permeabilization (Van
Cleemput et al., 2020). While EHV-1 can infect the respiratory
epithelium, previous in vivo, ex vivo and in vitro studies showed
that its replication is somehow restricted (Gryspeerdt et al., 2010;
Vandekerckhove et al., 2010; Hussey et al., 2014). The limited
replication of EHV-1 represents a finely tuned viral strategy
to control the innate immune responses at the primary site of
infection (Figure 2.1). On the one hand, this strategy allows a
limited number of EHV-1 particles present in the epithelium to
reach the cell bodies of TG neurons and to efficiently establish
latency. The virus is also able to modulate the recruitment of
circulating leukocytes to the URT. On the other hand, this
strategy prevents the onset of a strong immune response that
could be detrimental for the host. The interferon system (IFN)
is the most effective mechanism of the innate response against
viral infections, including EHV-1. Equine type 1 interferon
(IFNα/β) has been detected in nasal secretions and serum of
experimentally EHV-1-infected ponies the first 2 weeks post-
inoculation (Edington et al., 1989; Chong and Duffus, 1992).
The production of type I IFN was directly associated with a
self-limited EHV-1 infection of the respiratory epithelium and
short-duration of nasal shedding (Gryspeerdt et al., 2010). EHV-
1 activated the IFN response in the URT by upregulating the
expression of IFN-α mRNA and protein levels in EREC and
respiratory mucosal explants (Hussey et al., 2014; Poelaert et al.,
2018). However, it was demonstrated that EHV-1 modulates the
FIGURE 2 | EHV-1 immune evasive strategies. (1) Restricted replication at the URT: (a) EHV-1 infects respiratory epithelial cells; (b) Infected epithelial cells produce
type I IFN to limit viral spread within the upper respiratory tract (URT); (c) Infected epithelial cells produce pro-inflammatory cytokines and chemokines to recruit
immune cells to the site of infection; (d) CD172a+ cells and T lymphocytes migrate to the URT. EHV-1 uses these cells to cross the basement membrane (BM) and
penetrate the lamina propria. (2) Hijacking leukocytes for viral dissemination. EHV-1 silences its replication in immune cells to avoid detection by neutralizing
antibodies in the blood circulation and draining lymph nodes. EHV-1 only expresses immediate-early and early proteins in CD172a+ cells. All classes of EHV-1
proteins are expressed in T lymphocyte but viral assembly is blocked, and no progeny virions are released. (3) Cell-to-cell spread in the endothelium of target organs:
EHV-1 infected immune cells are transported via the blood circulation to the pregnant uterus (a) and CNS (b). The adhesion of infected immune cells to the
endothelial cells lining the blood vessels of target organs activates viral replication. New EHV-1 progeny virions are released from infected immune cells and
transferred to endothelial cells via (micro)fusion events. Dashed arrows represent further spread of virus particles through connective tissues or CNS. Drawings are
partially based on SMART servier medical art templates.
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IFN antiviral response in a virus strain-specific manner. The
replication of EHV-1 neurovirulent strains was more efficient
in explants treated with Ruxolitinib, an IFN signaling inhibitor,
compared to non-treated explants. In contrast, the replication
of EHV-1 non-neurovirulent strains was not altered in treated
explants with plaque size similar to control group. The authors
suggested that EHV-1 non-neurovirulent strains have developed
an anti-IFN mechanism to focus on a more efficient replication at
the level of the URT than neurovirulent strains.
Several ex vivo and in vitro studies further characterized the
innate immune responses to EHV-1 infection in the respiratory
epithelium. Soboll-Hussey and colleagues showed that EHV-1
induces the upregulation of toll-like receptors (TLR)-3 and TLR-
9 as well as inflammatory cytokines (e.g., IL-1, TNF-alpha, and
IL-6) and chemokines (e.g., IL-8, MCP-1) in EREC (Hussey
et al., 2014). In nasal mucosal explants, EHV-1 elicited the
production of chemokines (e.g., CCL2 and CCL5), already at
24 hpi, in order to attract target CD172a+ cells (Gryspeerdt
et al., 2010; Zhao et al., 2017). Using a chemotaxis assay, it was
demonstrated that EHV-1 upregulates the expression of CXCL9,
CXCL10, eBD2, and 3 in EREC and induces the recruitment
of CD172a+ cells and T lymphocytes to the site of infection
(Poelaert et al., 2019c; Van Cleemput et al., 2020). Both studies
indicated that primary replication of EHV-1 neurovirulent strains
in the URT attracted significantly more CD172a+ cells and T
lymphocytes to the infected epithelium than non-neurovirulent
strains. These results are in accordance with a previous ex vivo
study of Vandekerckhove and colleagues (Vandekerckhove et al.,
2010). EHV-1 neurovirulent strains are likely to favor rapid
infection of immune cells rather than efficient spread through the
epithelium. So far, two EHV-1 glycoproteins (gG and gp2) have
been shown to control the recruitment of leukocytes to the horse’s
respiratory tract. EHV-1 gG is a chemokine binding protein
(vCKBP), which binds to a broad range of chemokines, such as
IL-8 and CXCL1, with high affinity and subsequently blocks their
activity (Bryant et al., 2003). In vivo, an EHV-1 gG deleted mutant
induces a more pronounced inflammatory response compared
to the wild-type virus (von Einem et al., 2007). EHV-1 gG is
also able to inhibit migration of equine neutrophils in response
to equine recombinant IL-8 (Van de Walle et al., 2007). Using
a functional cell migration assay, the infection of EREC with a
EHV-1 deleted gG mutant was shown to increase the migration of
monocytic cells and T lymphocytes to the infected site (Poelaert
et al., 2019c). In addition, EHV-1 gp2 was identified as another
viral protein with similar chemokine-binding activities as gG,
that impedes the migration of immune cells to the URT. Besides,
EHV-1 early protein pUL56 (encoded by EHV-1 ORF1) has also
been shown to modulate the cytokine responses both in vivo
and in vitro (Soboll Hussey et al., 2011; Hussey et al., 2014).
pUL56 plays a major role in the downregulation of cell surface
Major Histocompatibility Complex type I (MHC I) in infected
cells (Ma et al., 2012; Huang et al., 2014, 2015). Soboll-Hussey
and colleagues demonstrated that EHV-1 infection significantly
down-regulates MHC I expression in EREC. Infection with a
deleted ORF1 mutant partially restored MHC I expression and
significantly increased chemokine expression and chemotaxis of
immune cells to EREC (Soboll Hussey et al., 2014). Therefore,
it was proposed that EHV-1 pUL56 has a dual function during
infection. On one hand, this protein modulates the recruitment of
leukocytes at the primary site of infection. On the other hand, it
downregulates MHC I expression on infected cells and allows the
virus to evade CTL-mediated cell lysis. This may explain why the
virus can still cause a viremia in the presence of CTL precursors
in the host (O’Neill et al., 1999; Kydd et al., 2006).
Hijacking Leukocytes: The “Trojan
Horse” Mechanism of EHV-1
Dissemination
Previous in vivo and ex vivo studies of the pathogenesis of EHV-
1 demonstrated that the virus misuses single leukocytes from the
URT to breach the BM into the connective tissues (Gryspeerdt
et al., 2010; Vandekerckhove et al., 2010; Figure 2.2). It was
demonstrated that the expression of late gC and gD proteins is
hampered in these cells at early stages of infection (Gryspeerdt
et al., 2012). These findings are in accordance with a study from
van der Meulen and colleagues, showing that the expression
of EHV-1 late proteins is hampered in circulating leukocytes
(van der Meulen et al., 2006). These studies suggest that an
early block in the replication cycle of EHV-1 protects infected
leukocytes from efficient recognition by the immune system.
This “Trojan horse” mechanism allows infected leukocytes to
disseminate in the blood circulation despite the presence of virus-
neutralizing antibodies. Still, the minority of PBMC expressing
viral glycoproteins at their cell surface were found to be resistant
to antibodies, suggesting that EHV-1 uses other strategies to
evade antibody-dependent cell lysis (van der Meulen et al., 2003).
Laval and colleagues further investigated the mechanisms of
how EHV-1 hijacks and modulates its replication in the main
carrier cells: CD172a+ cells. The authors demonstrated that the
replication of EHV-1 is highly restricted in these cells with less
than 10% infected compared to fully susceptible rabbit kidney
(RK-13) cells (Laval et al., 2015a, 2017). In addition, EHV-1
replication is mainly non-productive in these cells. EHV-1 non-
neurovirulent strains, but not neurovirulent strains, delay their
replication in CD172a+ cells at a very early time of infection. The
gene expression of EHV-1 non-neurovirulent strains is silenced
and tightly regulated by histone deacetylases (HDAC) in these
cells. Chromatin remodeling by HDAC plays a key role in the
regulation of viral gene expression during herpesvirus infections
(Sarkar et al., 2006; Guise et al., 2013). These findings suggest
that EHV-1 non-neurovirulent and neurovirulent strains use
distinct immune evasive strategies in target cells. Silencing gene
expression by HDAC might be an epigenetic strategy for EHV-
1 non-neurovirulent strains to slow down their replication and
persist longer in CD172a+ cells than neurovirulent strains. It
was proposed that mutations in the coding sequences of some
regulatory proteins of EHV-1 non-neurovirulent strains might
alter their capacity to bind and subsequently phosphorylate
HDAC and/or HDAC-containing complexes at viral promoters in
CD172a+ cells. This may result in increased levels of HDAC and
repression of EHV-1 gene expression, and thus may indirectly
delay viral replication in these cells. However, the fact that both
viral strains can still cause a viremia in vaccinated horses indicates
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that manipulation of HDAC is only one part of EHV-1’s strategy
to bypass detection by the immune system. Laval and colleagues
further investigated the molecular mechanisms underlying the
restricted infection of EHV-1 in CD172a+ cells (Laval et al.,
2016). Using dioctadecyloxacarbocyanine perchlorate (dio)-
labeled EHV-1 particles, the authors characterized the entry
mechanisms of EHV-1 in these cells. EHV-1 bound to a limited
number of CD172a+ cells compared to RK-13 cells, suggesting
that a block at the virus binding level might be partially
responsible for the restricted viral replication in these cells. These
results also suggest the presence of specific receptor(s) at the
cell surface. Previous studies have already shown that EHV-
1 uses a cell surface receptor that is distinct from any of the
known alphaherpesvirus entry receptors (Frampton et al., 2005).
MHC I has been identified as a functional entry receptor for
gD in equine dermal and brain microvascular EC (Kurtz et al.,
2010; Sasaki et al., 2011). However, a study from Azab and
colleagues demonstrated that MHC I antibodies do not efficiently
block EHV-1 entry into PBMC, indicating that different receptors
are present on equine leukocytes (Azab and Osterrieder, 2012).
Enzymatic removal of sialic acids present on the cell surface,
but not heparan sulfate, inhibited EHV-1 infection of CD172a+
cells by 90–100%. It was proposed that EHV-1 interacts with
a sialic acid-containing cell surface receptor expressed on these
cells. Future work is still needed to determine which sialylated
glycans are expressed on CD172a+ cells and involved in EHV-
1 binding step. Specific EHV-1 glycoprotein(s) that serve as
viral glycan-binding proteins should also be identified. EHV-
1 gC has hemagglutination activity against equine red blood
cells and is considered a potential viral lectin candidate for the
binding of sialic acid residues on CD172a+ cells (Andoh et al.,
2015). Moreover, the blockage of αvβ3 integrin by neutralizing
antibodies significantly reduced EHV-1 entry at a post-binding
step. αvβ3 integrin acts as a co-receptor for HSV1 and HCMV
(Wang et al., 2005; Gianni and Campadelli-Fiume, 2012). The
interaction between αvβ3 integrin present on PBMC and the
arginine, serine and aspartic acid (RSD) motif present in EHV-
1 gD is known to trigger EHV-1 entry via endocytosis (Van
de Walle et al., 2008). Therefore, it was proposed that EHV-
1 uses αvβ3 integrin to route its entry via endocytosis into
CD172a+ cells in order to shorten its exposure at the cell surface.
Finally, the authors demonstrated that EHV-1 enters CD172a+
cells via an endocytic mechanism that requires cholesterol,
tyrosine kinase activity, actin polymerization, dynamin activity,
and endosomal acidification, pointing toward a phagocytic
mechanism. Phagocytic mechanisms have already been described
for the entry of HSV1 and CMV into cells (Clement et al., 2006;
Tiwari and Shukla, 2012). The formation of protrusions at the
surface of CD172a+ cells mediated by actin polymerization may
facilitate uptake of EHV-1 into the cell and protect the virus from
neutralizing antibodies.
While CD172a+ cells are considered the main “Trojan horse”
in the pathogenesis of EHV-1, T lymphocytes also serve as an
important vehicle for viral dissemination. EHV-1 predominantly
infects T lymphocytes (CD4+) with EHV-1 non-neurovirulent
strains infecting twice as much cells (˜10%) than neurovirulent
strains (Poelaert et al., 2019b). Both type of strains efficiently
replicated in T lymphocytes with the expression of all classes
of viral proteins. However, viral glycoproteins clustered at the
plasma membrane of T lymphocytes and formed aggregates. Viral
capsids were also found to accumulate in the cell nucleus and the
release of progeny virions was hampered. The authors proposed
that the aggregation of membrane-bound viral proteins at the
cell surface and the blockage of virus assembly represent two
new immune evasive mechanisms that EHV-1 uses to prevent
efficient recognition of infected cells by antibodies. Interestingly,
contact of the infected T lymphocytes with either another T
lymphocyte or CD172a+ cell activated viral assembly and egress.
The transfer of infectious virus from T lymphocyte to target
cell was mediated by the polarization of microtubule-organizing
center (MTOC) and the accumulation of lymphocyte function-
associated antigen 1 (LFA1) at the site of contact. These events
resulted in the formation of a virological synapse between the two
cells. The authors further demonstrated that EHV-1 hijacks the
dynein motor proteins to catalyze the transport of viral progeny
along the microtubule network that connects the cellular nucleus
to the virological synapse. These findings show that cell-to-cell
spread is an essential viral mechanism to disseminate within the
host and evade immunosurveillance.
EHV-1 Transfer From Leukocytes to
Endothelial Cells: Unloading the Trojan
Horse
EHV-1-induced abortion and neurological disease are direct
results of viral spread from infected leukocytes to EC lining the
blood vessels of target organs, and their subsequent infection.
EHV-1 also relies on cell-to-cell spread to bypass antibody-
mediated immune responses for efficient transmission to the
endothelium (Figure 2.3).
Recently, several studies investigated the molecular
mechanisms of EHV-1 transmission from leukocytes to EC.
Laval and colleagues showed that EHV-1 infection significantly
increases adhesion of CD172a+ cells to equine EC. Antibody-
blocking experiments indicated that αVβ3, α4β1, and αLβ2
integrins partially mediate adhesion of infected CD172a+ cells
to EC (Laval et al., 2015b). The authors proposed that the
interaction of EHV-1 gD and αVβ3 integrin expressed at the
surface of CD172a+ cells activates PI(3)K and ERK/MAPK
signaling pathways. This event mediates EHV-1 entry into
CD172a+ cells at early time of infection. Later, activated
integrins expressed on infected CD172a+ cells interact with EC
ligands, facilitating immune cell adhesion to the endothelium.
The PI3K signaling pathway plays an important role in the
inflammatory response. PI3K isoform γ is highly expressed
in leukocytes and triggers chemokine-mediated recruitment
and activation of innate immune cells at inflammation sites
(Hawkins and Stephens, 2015). It was therefore suggested that
EHV-1 infection switches CD172a+ cells to a pro-inflammatory
phenotype to promote their differentiation into macrophages,
migration, and subsequent adhesion. However, another study
demonstrated that the release of cytokines and chemokines is
significantly reduced in PBMC upon EHV-1 infection (Pavulraj
et al., 2020). Besides, EHV-1 induces procoagulant activity in
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equine monocytic cells (Yeo et al., 2013). Tissue factor (TF) is
the primary activator of coagulation and is mainly produced
by monocytes in an inflammatory state (Østerud, 2010). It was
proposed that increased monocyte TF expression promotes
their adhesion to the endothelium and this process may be
involved in EHV-1-associated thrombosis. The adhesion of
EHV-1-infected CD172a+ cells to EC was found to correlate
with the production of pro-inflammatory cytokines, such as
TNF-α, in the microenvironment (Laval et al., 2015b). The
adhesion process is likely to create an inflammatory environment
that facilitates the recruitment of additional monocytic cells to
the endothelium. This inflammatory cascade may promote EC
infection. Additional factors present in the local environment of
the endothelium may influence the adhesion of leukocytes and
transfer of virus to EC. It was demonstrated that cytokines (e.g.,
IL-2) and hormones (e.g., 17-estradiol and equine chrorionic
gonadotropin) upregulate the expression of adhesion molecules
on EC (Smith et al., 2002). Consequently, the hormonal activity
and immune status of the pregnant mare may impact on the
efficient infection of the endothelium and the development
of abortion at late stage of pregnancy. Short-chain fatty acids
(SCFA), such as sodium butyrate and sodium propionate, are
metabolic end-products of the fermentation of dietary fibers.
Recently, SCFA were found to downregulate the expression of
ICAM-1 and VCAM-1 adhesion molecules on EC. Pretreatment
of EC with SCFA decreased adhesion of EHV-1 infected immune
cells to EC and viral transfer (Poelaert et al., 2019a).
Cell-to-cell contacts activate the transcription and translation
of viral proteins in infected CD172a+ cells and facilitate the
transfer of new progeny virions to EC (Laval et al., 2015b).
Infected T lymphocytes can also transfer virions to EC (Poelaert
et al., 2019b). Using an in vitro flow system that mimics the
rolling of PBMC to EC, Spiesschaert et al. (2015) demonstrated
that EHV-1 gB and US3 proteins mediate viral transfer to
EC in the presence of neutralizing antibodies. As a common
strategy for herpesviruses, EHV-1 uses cell-cell (micro) fusion
mechanisms for viral transmission (Laval et al., 2015b; Kamel
et al., 2020). However, this transfer seems to be mainly non-
productive (Laval et al., 2015b). These findings suggest that not
all infected leukocytes transfer EHV-1 to EC, not every transfer
leads to effective spread within the endothelium and not every
successful infection of EC causes infection of surrounding tissues.
Furthermore, it was shown that EHV-1 infection inhibits the
type I IFN response in EC in vitro (Sarkar et al., 2015). After an
early induction of type I IFN, EHV-1 suppresses the production
of IFN while increasing the expression of late viral genes in
EC. EHV-1 infection disrupts the interferon regulatory factor-
3 (IRF-3) signaling pathway in EC through downregulation of
endogenous IRF-3 protein level and inhibition of IRF3 nuclear
translocation (Sarkar et al., 2016a). Additional studies showed
that EHV-1 infection of EC suppresses the expression of TLR3
and TLR4 mRNA as well as the transcription of IRF7 and
IRF9 mRNA in order to evade type I IFN antiviral effects.
The virus also disrupts the JAK/STAT signaling pathway by
degrading cellular levels of TYK2 and thus, downregulates
downstream STAT1 and STAT2 phosphorylation levels (Sarkar
et al., 2016b; Oladunni et al., 2019). The suppression of key
factors in the induction of type I IFN only occurs after viral
DNA synthesis, suggesting that late viral proteins are involved in
the inhibition of STAT phosphorylation. The imbalance between
antiviral and pro-inflammatory immune responses has been
shown to play an important role in the clinical outcome of
alphaherpesviruses infection in vivo (Laval et al., 2019). It is likely
that EHV-1-mediated inhibition of type I IFN responses in EC
directly promotes efficient viral replication and spread in the
endothelium. In turn, this event favors the induction of a pro-
inflammatory environment that contributes to the development
of EHV-1-induced disease.
THERAPEUTIC APPROACHES BASED
ON CURRENT KNOWLEDGE OF THE
PATHOGENESIS OF EHV-1
Despite many years of research, there are currently no fully
protective vaccines against EHV-1 and no efficient antiviral
drugs. Current inactivated and live-attenuated vaccines fail to
fully prevent virus shedding, cell-associated viremia and EHV-
1-induced abortion and neurological disorders. The virus is still
able to spread via a cell-associated viremia in vaccinated horses.
Over the last 5 years, knowledge on the mechanisms of EHV-1
pathogenesis has dramatically increased. We can now think about
designing new therapeutics that selectively target key immune
evasive strategies developed by the virus at the level of the URT,
blood circulation, and endothelium of target organs to prevent or
mitigate future EHV-1 infections.
The first approach would be to prevent or restrict more
efficiently primary EHV-1 infection. The integrity of the
respiratory epithelium is often compromised by respiratory
hazards (e.g., pollens, mycotoxins, mucolytic agents) present
in the horse’s environment. The disruption of respiratory ICJ
facilitates EHV-1 infection of the URT. The use of aerosol drugs
that strengthen the respiratory epithelium may be an interesting
strategy to modulate primary EHV-1 infection. These drugs
should contain calcium to allow the stabilization of ICJ as well as
protease inhibitors to act on foreign incoming proteases arising
from pollens and other putative sources. The efficacy of aerosol
therapy in the prophylaxis and treatment of EHV-1 disease is
however speculative at this point (Van Cleemput et al., 2019a).
Moreover, EHV-1 infection of respiratory epithelial cells induces
the production of type I IFN that limits further spread of the
virus within the epithelium. Still, the IFN response is not enough
to prevent virus to migrate through the epithelium and infect
immune cells. The oral use of recombinant type I IFN could be
considered as an antiviral drug in EHV-1-infected horses to treat
primary infection. So far, the low dose administration of human
type I IFN to experimentally EHV-1 infected horses did not
show significant decrease in viral shedding and clinical disease
(Seahorn et al., 1990). The use of an equine recombinant type
I IFN at a higher dose might be more appropriate for in vivo
studies. Ultimately, the identification and subsequent targeting of
EHV-1 basolateral receptor in the respiratory epithelium might
be the best approach to fully block viral infection of the URT.
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The second approach would be to halt the migration of
immune cells to the primary site of infection and/or their
subsequent infection. EHV-1-infected epithelial cells produce
pro-inflammatory cytokines, chemokines, eBD2, and 3 to
attract immune cells. The use of anti-inflammatory aerosol
drugs that reduce the cytokine and chemokine responses (e.g.,
corticosteroids, cytokine/chemokine neutralizing antibodies,
cytokine signaling blockers) could be considered in combination
with antiherpesvirus therapies. As the mechanism of EHV-1
entry into target CD172a+ cells has been partially elucidated, it
would be relevant to examine the efficacy of entry blockers as
antivirals to prevent cell-associated viremia. Sialic acid residues
present on CD172a+ cells are essential in the initiation of EHV-
1 infection. The use of carbohydrate-binding molecules specific
for sialic acid demonstrated protective in vivo efficacy against
influenza virus and therefore could provide similar protection
against EHV-1 infection and other pathogens that recognize sialic
acid receptors (Connaris et al., 2014). As the replication of EHV-
1 non-neurovirulent strain is delayed and controlled by HDAC
in CD172a+ cells, it could be interesting to use specific HDAC
inhibitors in combination with potent antiviral drugs to prevent
cell-associated viremia. Highly selective HDAC inhibitors may
relieve EHV-1 temporary block in viral gene expression and
accelerate viral replication in monocytic cells. Subsequently,
antiviral treatment may efficiently inhibit viral replication in
these cells before they reach the target epithelium. Vaccination
prior to HDAC inhibitors treatment could boost the immune
response and also facilitate the clearance of infected cells.
However, these approaches are contingent on the availability
of potent antivirals and vaccine candidates on the market. As
HDAC do not control replication of EHV-1 neurovirulent strains
in CD172a+ cells, it is important to keep in mind that HDAC
inhibitors may not be useful for horses with EHV-1-related
neurological disorders or already showing symptoms.
The third approach would be to prevent the adhesion of
EHV-1-infected immune cells to the endothelium of target
organs. Transient administration of anti-adhesive agents that
interfere with immune cell adhesion should be explored in vivo
as a potential mitigation strategy for EHV-1-induced abortion
and neurological disorders. A complete characterization of the
adhesion molecules present on both immune cells and EC is
beforehand required. Anti-inflammatory drugs have also been
shown to decrease EC infection by reducing contact between
EHV-1-infected PBMC and EC (Goehring et al., 2017). The
administration of corticosteroids and anti-inflammatory drugs
has been recommended for a short duration in EHM treatment,
but no data has demonstrated their potential efficacy so far.
SCFA have been shown to reduce leukocyte adhesion to EC
in vitro. SCFA have anti-inflammatory properties and hence a
high-fiber diet or diet supplemented with SFCA could potentially
reduce systemic inflammation and ultimately prevent EHV-1-
associated disease.
CONCLUDING REMARKS
EHV-1 is able to impair horses’ health and affect equine industry
all over the world. Over the last decade, the interest in EHV-1 has
significantly increased due to frequent outbreaks of neurological
disease and abortions caused by the virus. Within a global horse
population of 58 million including 6 million in Europe, the
high incidence of EHV-1 and severe associated symptoms raise
serious health and economical concerns to the equine industry.
Despite many years of research, no fully protective vaccines
against EHV-1 or efficient antiviral drugs have been developed.
Treatment is mainly limited to supportive therapy. The main
reason is that EHV-1 uses a plethora of immune mechanisms
to bypass the host’s immune response. A major breakthrough
in our understanding of the pathogenesis of EHV-1 is therefore
urgently needed. In this review, we summarize recent findings
on the key immune evasive strategies used by the virus at main
sites of infection: the URT, blood circulation, and endothelium of
target organs. Their targeting may be a new and more effective
therapeutic option to fight against EHV-1 infection.
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